Navigation Links
Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter
Date:7/23/2009

ses and non-GAAP operating margin, (ii) financial guidance for the fiscal quarter ending September 26, 2009, including guidance regarding revenue, non-GAAP gross margin and adjusted EBITDA and revenue outlook for the remainder of 2009, (iii) the impact of the acquisition of Avanex Corporation and the Spectra-Physics asset swap on the combined entity's gross margin, (iv) sources for improvement of gross margin and operating expenses, including supply chain synergies, optimizing mix of product offerings, transition to higher margin product offerings, benefits of combined R&D and sales organizations and single public company costs, (v) the expected first year financial opportunities, including becoming profitable in 12 months, obtaining quarterly operating cash breakeven (non-GAAP) by end of first year, expected synergies per quarter by end of the fourth full quarter after close of the merger with Avanex Corporation and restructuring costs, (vi) opportunities to grow in adjacent markets and (vii) statements containing the words "target," "believe," "plan," "anticipate," "expect," "estimate," "will," "should," "ongoing," and similar expressions. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the impact of continued uncertainty in world financial markets and the resulting reduction in demand for our products, the future performance of Oclaro, Inc. following the closing of the merger with Avanex Corporation and the Spectra-Physics asset swap, the inability to realize the expected benefits and synergies as a result of the of the merger with Avanex Corporation and the Spectra-Physics asset swap, increased costs related to downsizing and compliance with regulatory compliance in connection with such downsizing, the lack of availability of credit or opportunity for equity based financing, as well as the factors described in Oclaro's most recent regis
'/>"/>
SOURCE Oclaro, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Oclaro Launches Eye-Safe High Power Laser Diodes at LASER 2009
2. Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatment for MS
3. Zimmer Holdings, Inc. Reports Second Quarter 2009 Financial Results
4. Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
5. Digirad Corporation Reports Second Quarter 2009 Financial Results
6. Affymetrix Reports Second Quarter 2009 Results
7. Exponent Reports Second Quarter 2009 Results
8. Endologix Reports 42% Second Quarter 2009 Revenue Growth
9. Universal Health Realty Income Trust Reports 2009 Second Quarter Financial Results
10. Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
11. Amylin Pharmaceuticals Reports Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes in ... from everyday life changes can lead to very serious, life-altering events. Fortunately nature ... with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic doses of ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the ... societal issues and needs. Money for Good 2015, released today by Camber Collective, goes ... an annual potential to mobilize up to $22B in new philanthropic giving and shift ...
(Date:9/1/2015)... London, UK (PRWEB) , ... ... ... are constantly seeking better therapeutic options to efficiently cure and prevent different ... classes. Different cancers have different pathophysiological properties due to which distinctive approach ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Splashtop Business for Remote Support , a solution optimized for MSPs and ... with the escalating renewal prices and inadequate customer services of existing remote support ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, ... Touch® , an innovative vaginal health laser procedure that prevents and resolves dryness ... for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... nasal steroids don,t lessen symptoms , , TUESDAY, Dec. 4 ... better than a placebo in combating sinus infections, a ... as effective as have been previously believed, particularly for ... author Dr. Ian Williamson, a senior lecturer in primary ...
... Tampa, Fla. (December 4, 2007) A study carried ... Medicine and published in the current issue of CELL ... bone marrow cells (BMCs) containing adult stem cells are ... bio-engineered materials, they successfully help regenerate damaged nerves. The ...
... and OMX Nordic Exchange: EPCT) announced today the pricing ... common stock at $1.50,per share and five-year warrants to ... at an exercise price of $1.50 per share.,EpiCept will ... Rodman & Renshaw, LLC, a subsidiary of Rodman & ...
... Biopure Corporation,(Nasdaq: BPUR ) announces the ... Society for Clinical Pharmacology and Therapeutics annual,meeting to ... the largest scientific,and professional organization serving the discipline ... for adverse event outcomes and other,key findings in ...
... mice use energy less efficiently, researchers report in the ... Press, that they have delayed the animals deaths and ... and one form of cancer. Those health benefits, driven ... any direct influence on the aging process itself, according ...
... HOUSTON, Dec. 4, 2007 -- Robotics engineers at Rice ... develop a PC-based system for physical rehabilitation. , "It ... to regain the use of their limbs," said system ... Interfaces Laboratory (MAHI). "We hope to refine our system ...
Cached Medicine News:Health News:Sinusitis Treatments Found Ineffective 2Health News:Sinusitis Treatments Found Ineffective 3Health News:Bone marrow cell transplants help nerve regeneration 2Health News:EpiCept Corporation Announces Pricing of Public Offering 2Health News:EpiCept Corporation Announces Pricing of Public Offering 3Health News:Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics 2Health News:Fighting diseases of aging by wasting energy 2Health News:Fighting diseases of aging by wasting energy 3Health News:Robotics lab helps stroke patients with recovery 2
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... Sept. 1, 2015  Dynatronics Corporation (NASDAQ: ... at the First Annual Ladenburg Thalmann Healthcare Conference ... Kelvyn H. Cullimore, Jr. , Chairman and ... investment representatives on Tuesday, September 29 at 10:30 ... Conference will showcase leading-edge companies in the healthcare ...
(Date:9/1/2015)... -- Dr. Cindy Orser , the Chief Science Officer ... of DigiPath, Inc. (OTCQB: DIGP), was recently interviewed ... consistency in today,s medical cannabis testing industry. In her ... she explained that the state-to-state variations in cannabis laws ... makes standardization impossible. Dr. Orser is ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... China , April 29 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. (NYSE ... pharmaceuticals company in China , today announced,that it has retained CCG ... , , ... to working with CCG to establish more effective and,transparent communications channels with ...
... , April 29 Royal Philips Electronics ( ... provider of integration solutions in healthcare, to deploy the Orion Health Rhapsody® ... , , ... , , ...
Cached Medicine Technology:China Pharma Holdings, Inc. Retains CCG Investor Relations 2China Pharma Holdings, Inc. Retains CCG Investor Relations 3China Pharma Holdings, Inc. Retains CCG Investor Relations 4China Pharma Holdings, Inc. Retains CCG Investor Relations 5Philips and Orion Health Partner to Deliver on Enterprise Interoperability 2Philips and Orion Health Partner to Deliver on Enterprise Interoperability 3Philips and Orion Health Partner to Deliver on Enterprise Interoperability 4
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
... The Carriazo-Pendular microkeratome is based ... of the cornea during the cut., ... applanated evenly from the beginning of ... ensures that the intraocular pressure does ...
Medicine Products: